Creative Biolabs is a leading CRO company for the development of antibodies for research, diagnostic, and therapeutic purposes. With advanced hybridoma and phage display technologies, we offer a wide range of customized solutions for the development of both monoclonal and polyclonal antibodies of different species for in vitro diagnostic (IVD) tests. Here, we introduce the biomarkers and IVD antibody/immunoassay development services for acute pancreatitis.
Acute pancreatitis, an inflammatory disorder of the pancreas, is a potentially life-threatening disease affecting both women and men. Risk factors include gallstones, alcohol misuse, drugs, other diseases, endoscopic retrograde cholangiopancreatography, and so on. Acute pancreatitis can present with varying severity (mild, moderate, and severe). In more than 80% of patients, acute pancreatitis is mild and resolves without serious morbidity, but in up to 20% it can be severe and complicated by major morbidity and mortality. Moderate acute pancreatitis is characterized by the presence of transient organ failure or local/systemic complications. Persistent organ failure, however, is the feature of severe acute pancreatitis, leading to a high rate of mortality.
The diagnosis of acute pancreatitis is usually based on a combination of history and examination, abnormal laboratory investigations and radiological evidence of pancreatic inflammation. Acute pancreatitis typically presents with severe, constant upper abdominal pain which may radiate through to the back and be associated with nausea and vomiting. Give the non-specific nature of these symptoms, confirmatory tests are needed to confirm the diagnosis, including laboratory tests (pancreatic enzyme tests) and imaging tests (e.g., contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (MRI)). The pancreatic enzymes that are often measured include amylase and lipase. Now biomarkers that have the potential to improve the diagnostic accuracy of acute pancreatitis include trypsinogens, phospholipase A2, pancreatic elastase, urine trypsinogen activated protein (TAP) and carboxypeptidase B (CAPB).
Immunoassays allow the detection and quantification of various antigens and/or antibodies in different types of samples (serum, plasma, urine, saliva, environmental media…). They are based on the specific recognition between one or more antibodies and an antigen. These assays can be difficult to develop and validate, with challenges in the establishment of method selectivity, specificity, and range of quantitation resulting from nonspecific background signal, matrix interference, lack of linearity and antibody interference. Moreover, the selection of appropriate assay formats, as well as purity/quality of reagents (especially critical raw materials), are also of great importance.
Supported by our versatile IVD platform, Creative Biolabs offers contract research services for the development of high-quality IVD antibodies targeting a wide range of disease biomarkers. Moreover, we help with the development and validation of different immunoassays, such as lateral flow immunoassays and ELISA tests. For more information please click the links below:
For pancreatitis, we focus on various biomarkers including but not limited to:
Please feel free to contact us to discuss your project requirements.
References
For Research Use Only.
